v3.25.2
Income Taxes (Details Narrative) - Sonnet BioTherapeutics Holdings, Inc. [Member] - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Sep. 30, 2024
Sep. 30, 2023
Aug. 31, 2022
Effective Income Tax Rate Reconciliation [Line Items]              
Tax credit carryforwards         $ 3,129,222 $ 3,106,675  
Increase (decrease) in valuation allowance         (600,000) 5,800,000  
Other income $ 720,102 $ 4,327,946 4,327,946  
Excise tax             1.00%
Minimum [Member]              
Effective Income Tax Rate Reconciliation [Line Items]              
Corporate alternative tax             15.00%
New Jersey Division of Taxation [Member]              
Effective Income Tax Rate Reconciliation [Line Items]              
State of net operating losses         49,400,000 $ 0  
Sale of unused research and development tax credits         300,000    
Other income         4,400,000    
Domestic Tax Jurisdiction [Member]              
Effective Income Tax Rate Reconciliation [Line Items]              
Net operating losses         107,500,000    
Tax credit carryforwards         2,600,000    
State and Local Jurisdiction [Member]              
Effective Income Tax Rate Reconciliation [Line Items]              
Net operating losses         24,400,000    
Tax credit carryforwards         500,000    
Foreign Tax Jurisdiction [Member]              
Effective Income Tax Rate Reconciliation [Line Items]              
Net operating losses         $ 16,000,000.0